A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy Cancer neoantigens and neoantigen-specific T…
Fundación BBVA
After more than a decade of research, a new-generation CAR-T therapy developed by VHIO, in collaboration with the Hospital del…
Co-led by Rodrigo Toledo and Elena Garralda, IMMUNOMICS-VHIO is a platform for the discovery and validation of liquid biopsy biomarkers…
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy…
Engineering T cells directly inside the patient’s body to turn them into CAR-T cells ready to attack tumor cells, using…
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by…
Co-authored by investigators of VHIO’s Cancer Genomics Group and Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, results…
The ultrasensitive liquid biopsy technique applied in this work is based on the sequencing of the entire tumour genome from…
